Related Experiment Video
Updated: Jul 6, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor
Katia Bifulco1, Immacolata Longanesi-Cattani, Lucia Gargiulo
1Department of Experimental Oncology, National Cancer Institute of Naples, via M. Semmola, 80131 Naples, Italy.
Abstract:
Urokinase receptor (uPAR) plays a key role in physiological and pathological processes sustained by an altered cell migration. We have developed peptides carrying amino acid substitutions along the Ser(88)-Arg-Ser-Arg-Tyr(92) (SRSRY) uPAR chemotactic sequence. The peptide pyro glutamic acid (pGlu)-Arg-Glu-Arg-Tyr-NH2 (pERERY-NH(2)) shares the same binding site with SRSRY and competes with N-formyl-Met-Leu-Phe (fMLF) for binding to the G-protein-coupled N-formyl-peptide receptor (FPR). pERERY-NH(2) is a dose-dependent inhibitor of both SRSRY- and fMLF-directed cell migration, and prevents agonist-induced FPR internalization and fMLF-dependent ERK1/2 phosphorylation. pERERY-NH(2) is a new and potent uPAR inhibitor which may suggest the generation of new pharmacological treatments for pathological conditions involving increased cell migration.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Cell Migration
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

